Robert

Sidbury

MD

MPH

Appointments

Seattle Children's

Biography

Robert Sidbury MD, MPH got his undergraduate and medical degrees from Duke University, and his Masters in Public Health from Harvard. He did his internship and residency at UCSF and the Oregon Health and Science University, and completed fellowships at Northwestern University and Harvard.  He has held faculty positions at Harvard Medical School and the University of Washington School of Medicine where he is currently Associate Professor in the Department of Pediatrics and Chief of the Division of dermatology.  His clinical and research interests include atopic dermatitis, vascular tumors of infancy, vitamin D, and pediatric health services. Dr. Sidbury is currently site PI for clinical trials of biologic medications for AD including dupilumab and nemolizumab, as well as a trial of a topical anticholinergic agent for hyperhidrosis.  Past trials have focused on epidermolysis bullosa, hemangiomas, among other diseases. He spends most of his time outside of work playing with his four year old daughter Claire.

Education & Training

MD, Duke University School of Medicine, Durham, NC (1993)

Residency in Dermatology, Oregon Health Sciences University, Portland OR (1995-1998)

MPH, Harvard School of Public Health, Boston MA (2008)

B.S., Duke University, Durham NC (1985)

Honors

UW Derm John E. Olerud Resident Teaching Award (2014)

Presidential Citation, American Academy of Dermatology (2011)

Research Interests

• Site PI for clinical trials of biologic medications for AD including dupilumab and nemolizumab
• Trial of a topical anticholinergic agent for hyperhidrosis.  
• Past trials have focused on epidermolysis bullosa, hemangiomas, among other diseases.

Clinical Interests

• Pediatric dermatology
• Atopic dermatitis
• Vascular tumors of infancy
• Vitamin D
• Pediatric health services research

Publications

Selected Publications

Merola J, Sidbury R, Wollenberg A et al.  Dupilumab Prevents Flares in Adults With Moderate-To-Severe Atopic Dermatitis in a 52-week Randomized Controlled Phase 3 Trial.  J Am Acad Dermatol 2020 May

Sidbury R.  Should pediatricians be more proactive in counseling children about skin cancer risk?  Implications of the USPSTF  recommendation statement.  JAMA Pediatr 2018 Mar 20

Khorsand K, Sidbury R.  The Shadow Clinic: Emails, curbsides, and “quick peeks” in pediatric dermatology.  Pediatr Dermatol 2019;36(5):607-10

Togias A, Cooper SF, Acebal ML, Assa’ad A, Baker JR Jr, Beck LA, Block J, Byrd C, Chan LS, , Eichenfield LF, Fleischer DM, Fuchs GJ 3rd, Furuta GT, Greenhawt MJ, Gupta RS, Habich M, Jones SM, Keaton K, Muraro A, Plaut M, Rosenwasser LJ, Retrosen D, Sampson HA, Schneider LC, Sicherer SH,  Sidbury R Spergel J, Stukus DR, Venter C, Boyce JA.  Addendum Guidelines for the prevention of peanut allergy in the United States:  Report of the National Institute for Allergy and Infectious Diseases-sponsored expert panel. J Allergy Clin Immunol 2017;139(1)29-44

Sidbury R, Davis DM, Cohen DE, Cordoro K Berger T, Bergman J, Chamlin SL, Cooper K Feldman SR, Hanifin J, Krol A Margolis D, Paller AS, Schwarzenberger K, Silverman R, Simpson E,  Tom WT Williams HC, Elmets C, Block J, Harrod CG, Smith Begolka W, Eichenfield LF Guidelines of care for the management of atopic dermatitis.  Section 3:  Phototherapy and systemic treatment.  J Am Acad Dermatol; 2014 Aug;71(2):327-49  PMID: 24813298